Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A scalp hair loss condition characterized by excessive shedding of hair in the resting phase of growth, usually following a fever or major body stress.
Biomarker and diagnostic research for telogen effluvium has been reported in the published literature.
3 clinical trials registered, 1 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 1 PHASE2, 2 NA. Research is primarily industry-sponsored.
138 publications have been identified in PubMed for telogen effluvium. Research spans Review / Meta-Analysis (38%), Epidemiology / Natural History (26%), and Clinical Trial Publication (9%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 53 | 38% |
Data assembled from 3 of 12 sources · Last updated Oct 3, 2026, 10:14 AM UTC
Disease patterns and progression |
36 |
26% |
Clinical study results | 12 | 9% |
Other research | 11 | 8% |
Patient case studies | 10 | 7% |
Laboratory research | 9 | 7% |
New treatment approaches | 5 | 4% |
Testing and diagnosis research | 2 | 1% |
Baker NJ (2026). [PMID: 42200572](https://pubmed.ncbi.nlm.nih.gov/42200572/). *J Cutan Med Surg*. [Other]
Zarabian N (2026). [PMID: 42210891](https://pubmed.ncbi.nlm.nih.gov/42210891/). *Dermatol Surg*. [Review / Meta-Analysis]
Shome D (2026). [PMID: 41615642](https://pubmed.ncbi.nlm.nih.gov/41615642/). *Stem Cell Rev Rep*. [Review / Meta-Analysis]
Poniatowska O (2026). [PMID: 41484546](https://pubmed.ncbi.nlm.nih.gov/41484546/). *Dermatol Ther (Heidelb)*. [Review / Meta-Analysis]
Ruiz Dueñas A (2026). [PMID: 42100246](https://pubmed.ncbi.nlm.nih.gov/42100246/). *Front Med (Lausanne)*. [Case Report / Case Series]
Alomary SA (2026). [PMID: 42239846](https://pubmed.ncbi.nlm.nih.gov/42239846/). *J Clin Aesthet Dermatol*. [Epidemiology / Natural History]
Argobi Y (2026). [PMID: 41914454](https://pubmed.ncbi.nlm.nih.gov/41914454/). *J Cosmet Dermatol*. [Epidemiology / Natural History]
Seyed Jafari SM (2026). [PMID: 41957308](https://pubmed.ncbi.nlm.nih.gov/41957308/). *Am J Clin Dermatol*. [Review / Meta-Analysis]
Edelkamp J (2026). [PMID: 41664424](https://pubmed.ncbi.nlm.nih.gov/41664424/). *Exp Dermatol*. [Diagnostic / Biomarker]
Asfour L (2026). [PMID: 40747681](https://pubmed.ncbi.nlm.nih.gov/40747681/). *Clin Exp Dermatol*. [Epidemiology / Natural History]